載入...
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial
IMPORTANCE: Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2–positive breast cancer, by modulating antibody-dependent...
Na minha lista:
| 發表在: | JAMA Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5344747/ https://ncbi.nlm.nih.gov/pubmed/27812689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.4884 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|